{"entity":{"id":"nct06584032","kind":"trial","name":"Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer","aka":[],"tldr":"A phase 3 trial of Fruquintinib, Sintilimab, Paclitaxel / nab-paclitaxel in endometrial cancer, run by Hutchmed, now recruiting.","summary":"Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer is a phase 3 interventional study registered as NCT06584032 by Hutchmed, with 412 participants planned, started 2024-12-12 and due to reach its primary completion in 2029-01-08. Interventions recorded: fruquintinib, sintilimab, paclitaxel, doxorubicin. Conditions listed: Advanced Endometrial Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06584032","url":"https://clinicaltrials.gov/study/NCT06584032"}],"tags":["ctgov-ingest"],"related":[],"cancers":["endometrial","advanced-recurrent-endometrial-cancer"],"sections":[],"technologies":["antiangiogenic","checkpoint-inhibitor","kinase-inhibitors","monoclonal-antibody"],"targets":[],"drugs":["fruquintinib","sintilimab","paclitaxel","doxorubicin"],"companies":["hutchmed"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06584032","phase":"3","setting":"A Randomized,Open-label,Multicenter Phase III Clinical Study to Evaluate the Efficacy and Safety of Fruquintinib Plus Sintilimab Versus Chemotherapy of the Treating Physician's Choice as Second-line Treatment for Advanced Endometrial Cancer","sponsor":"Hutchmed","started":"2024-12-12","startedType":"actual","enrolled":412,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06584032/","neighbours":{"cancer":[{"id":"advanced-recurrent-endometrial-cancer","kind":"cancer","name":"Advanced or recurrent endometrial cancer","route":"/cancers/advanced-recurrent-endometrial-cancer/"},{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"doxorubicin","kind":"drug","name":"Doxorubicin","route":"/drugs/doxorubicin/"},{"id":"fruquintinib","kind":"drug","name":"Fruquintinib","route":"/drugs/fruquintinib/"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"},{"id":"sintilimab","kind":"drug","name":"Sintilimab","route":"/drugs/sintilimab/"}],"company":[{"id":"hutchmed","kind":"company","name":"Hutchmed","route":"/companies/hutchmed/"}]}}